ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

NCT04143607 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic NSCLC

Interventions

DRUG: ASK120067
DRUG: Placebo Gefitinib 250 mg
DRUG: Gefitinib
DRUG: Placebo ASK120067

Sponsor

Jiangsu Aosaikang Pharmaceutical Co., Ltd.